New directions in multiple sclerosis therapy: matching therapy with pathogenesis

Area of Science:

• Neuroimmunology
• Multiple Sclerosis Pathophysiology

Background:

• Current multiple sclerosis (MS) therapies primarily target systemic immune responses before they enter the central nervous system (CNS).
• These treatments often lack efficacy in the progressive phases of MS and can increase risks of infections and neoplastic disorders.
• A need exists for therapies that are effective across all disease stages and minimize systemic toxicity.

Purpose of the Study:

• To explore disease-related mechanisms within the CNS that drive the distinct phases of MS (relapses, remission, progression).
• To identify potential therapeutic targets within the CNS for improved MS management.
• To consider CNS-specific immunologic properties and neural cell functions in therapeutic development.

Main Methods:

• Review of existing data on MS pathogenesis.
• Analysis of CNS-specific immunologic mechanisms, including innate immunity.
• Evaluation of neural cell-related properties influencing tissue injury and repair in MS.

Main Results:

• Approved MS therapies primarily target peripheral immune cells, showing limited impact on disease progression.
• CNS-specific mechanisms, particularly involving the innate immune system and neural cells, are critical determinants of MS progression.
• These CNS-intrinsic processes represent potential targets for novel therapeutic strategies.

Conclusions:

• Future MS therapies should focus on CNS-intrinsic mechanisms to effectively address disease progression.
• Targeting CNS immunologic properties and neural cell functions could lead to more efficacious and safer treatments for all phases of MS.
• Understanding these localized mechanisms is key to developing disease-modifying therapies with reduced systemic side effects.